{"hands_on_practices": [{"introduction": "This exercise grounds our understanding of Therapeutic Drug Monitoring (TDM) in its most fundamental principle: the relationship between dosing rate and drug clearance ($CL$). We will explore how a change in a patient's physiological state, such as an acute kidney injury, directly impacts drug elimination. By deriving the dose adjustment formula from first principles, you will solidify your grasp on the mass-balance concept at steady state and learn to quantify the consequences of both correct and incorrect dosing decisions [@problem_id:4585045].", "problem": "A patient with stable chronic infection is receiving an intravenous antimicrobial agent monitored by Therapeutic Drug Monitoring (TDM). The pharmacokinetics are linear, consistent with a one-compartment model with first-order elimination. Before an acute kidney injury, the patient had been maintained at a target average steady-state concentration using a maintenance dose of $850\\,\\text{mg}$ administered every $\\tau = 12\\,\\text{h}$, with intravenous bioavailability $F = 1$. After the kidney injury, the drug’s systemic clearance decreased by $30\\%$, while bioavailability and volume of distribution are unchanged. The dosing interval remains fixed at $\\tau = 12\\,\\text{h}$.\n\nUsing only fundamental definitions (mass balance at steady state, the definition of clearance as the proportionality between drug elimination rate and concentration, and the definition of average steady-state concentration over a dosing interval), derive the relationship needed to compute a maintenance dose that preserves the same average steady-state concentration after the change in clearance. Then compute:\n- the new maintenance dose per administration (in $\\text{mg}$) required to maintain the same average steady-state concentration as before, and\n- the multiplicative change in the average steady-state concentration (expressed as a dimensionless decimal) that would be expected if the original $850\\,\\text{mg}$ every $12\\,\\text{h}$ regimen were mistakenly continued after the $30\\%$ decrease in clearance.\n\nRound both results to four significant figures. Express the maintenance dose in $\\text{mg}$ and the multiplicative change as a dimensionless decimal (not a percentage).", "solution": "The problem is deemed valid as it is scientifically grounded in the principles of pharmacokinetics, is well-posed with sufficient and consistent data, and is expressed in objective, formal language. We will proceed with a solution.\n\nThe problem requires a derivation of the maintenance dose relationship from fundamental principles, followed by two calculations.\n\n**1. Derivation of the Fundamental Relationship**\n\nLet $D$ be the maintenance dose administered, $F$ be the bioavailability, and $\\tau$ be the dosing interval. The pharmacokinetics follow a one-compartment model with first-order elimination. At steady state, the rate of drug administration must equal the rate of drug elimination when averaged over one dosing interval, $\\tau$.\n\nThe average rate of drug input into the systemic circulation is the total bioavailable dose divided by the dosing interval:\n$$ \\text{Average Rate In} = \\frac{D \\cdot F}{\\tau} $$\n\nThe instantaneous rate of drug elimination is defined as the product of the systemic clearance, $CL$, and the drug concentration at time $t$, $C(t)$:\n$$ \\text{Rate of Elimination}(t) = CL \\cdot C(t) $$\n\nThe average rate of elimination over a dosing interval at steady state is the integral of the instantaneous rate over the interval, divided by the interval duration:\n$$ \\text{Average Rate Out} = \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} CL \\cdot C_{ss}(t) \\,dt $$\nwhere $C_{ss}(t)$ is the drug concentration at time $t$ during a steady-state interval. Since clearance, $CL$, is a constant for a given patient state, it can be moved outside the integral:\n$$ \\text{Average Rate Out} = CL \\cdot \\left( \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} C_{ss}(t) \\,dt \\right) $$\n\nThe term in the parentheses is the definition of the average steady-state concentration, $C_{ss,avg}$:\n$$ C_{ss,avg} = \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} C_{ss}(t) \\,dt = \\frac{\\text{AUC}_{ss,\\tau}}{\\tau} $$\nwhere $\\text{AUC}_{ss,\\tau}$ is the area under the concentration-time curve over one dosing interval at steady state.\n\nTherefore, the average rate of elimination can be expressed as:\n$$ \\text{Average Rate Out} = CL \\cdot C_{ss,avg} $$\n\nAt steady state, the average rate of drug input equals the average rate of drug output:\n$$ \\frac{D \\cdot F}{\\tau} = CL \\cdot C_{ss,avg} $$\n\nThis is the fundamental relationship connecting maintenance dose, bioavailability, dosing interval, clearance, and average steady-state concentration. This equation can be rearranged to solve for $C_{ss,avg}$:\n$$ C_{ss,avg} = \\frac{D \\cdot F}{CL \\cdot \\tau} $$\n\n**2. Calculation of the New Maintenance Dose**\n\nLet the initial state (before kidney injury) be denoted by subscript $1$ and the final state (after kidney injury) by subscript $2$.\n\nThe givens are:\n- Initial dose: $D_1 = 850\\,\\text{mg}$\n- Dosing interval (constant): $\\tau_1 = \\tau_2 = \\tau = 12\\,\\text{h}$\n- Bioavailability (constant, intravenous): $F_1 = F_2 = F = 1$\n- The clearance decreases by $30\\%$: $CL_2 = CL_1 - 0.30 \\cdot CL_1 = 0.70 \\cdot CL_1$.\n\nThe goal is to find the new dose, $D_2$, that maintains the same average steady-state concentration, i.e., $C_{ss,avg,2} = C_{ss,avg,1}$.\n\nUsing the derived relationship for both states:\n$$ C_{ss,avg,1} = \\frac{D_1 \\cdot F}{CL_1 \\cdot \\tau} $$\n$$ C_{ss,avg,2} = \\frac{D_2 \\cdot F}{CL_2 \\cdot \\tau} $$\n\nSetting $C_{ss,avg,2} = C_{ss,avg,1}$:\n$$ \\frac{D_2 \\cdot F}{CL_2 \\cdot \\tau} = \\frac{D_1 \\cdot F}{CL_1 \\cdot \\tau} $$\n\nThe terms $F$ and $\\tau$ are constant and non-zero, so they cancel:\n$$ \\frac{D_2}{CL_2} = \\frac{D_1}{CL_1} $$\n\nSolving for $D_2$:\n$$ D_2 = D_1 \\cdot \\frac{CL_2}{CL_1} $$\n\nThis equation shows that to maintain a constant average steady-state concentration, the dose must be adjusted in direct proportion to the change in clearance. Substituting the relationship $CL_2 = 0.70 \\cdot CL_1$:\n$$ D_2 = D_1 \\cdot \\frac{0.70 \\cdot CL_1}{CL_1} = 0.70 \\cdot D_1 $$\n\nNow, we compute the numerical value for $D_2$:\n$$ D_2 = 0.70 \\times 850\\,\\text{mg} = 595\\,\\text{mg} $$\n\nRounding to four significant figures, the new maintenance dose is $595.0\\,\\text{mg}$.\n\n**3. Calculation of the Multiplicative Change in Concentration**\n\nThis part assesses the consequence of mistakenly continuing the original dose ($D_1$) after the clearance has decreased. Thus, we set $D_2 = D_1 = 850\\,\\text{mg}$. We need to find the multiplicative change, which is the ratio $\\frac{C_{ss,avg,2}}{C_{ss,avg,1}}$.\n\nUsing the expressions for $C_{ss,avg,1}$ and $C_{ss,avg,2}$:\n$$ \\frac{C_{ss,avg,2}}{C_{ss,avg,1}} = \\frac{\\frac{D_2 \\cdot F}{CL_2 \\cdot \\tau}}{\\frac{D_1 \\cdot F}{CL_1 \\cdot \\tau}} $$\n\nSince $D_2=D_1$, $F$ is constant, and $\\tau$ is constant, the expression simplifies to:\n$$ \\frac{C_{ss,avg,2}}{C_{ss,avg,1}} = \\frac{CL_1}{CL_2} $$\n\nThis shows that if the dose is held constant, the average steady-state concentration changes inversely with clearance. Substituting $CL_2 = 0.70 \\cdot CL_1$:\n$$ \\frac{C_{ss,avg,2}}{C_{ss,avg,1}} = \\frac{CL_1}{0.70 \\cdot CL_1} = \\frac{1}{0.70} $$\n\nNow, we compute the numerical value:\n$$ \\frac{1}{0.70} \\approx 1.4285714... $$\n\nRounding to four significant figures, the multiplicative change in the average steady-state concentration is $1.429$.", "answer": "$$\\boxed{\\begin{pmatrix} 595.0 & 1.429 \\end{pmatrix}}$$", "id": "4585045"}, {"introduction": "Effective TDM requires looking beyond total drug concentration to the pharmacologically active free drug. This practice addresses the critical issue of altered plasma protein binding, a common confounder in clinical practice, particularly for highly-bound drugs like phenytoin. You will use a standard clinical correction formula to adjust a measured concentration for hypoalbuminemia, but more importantly, you will delve into the assumptions and limitations of such corrections, fostering critical clinical judgment [@problem_id:4584994].", "problem": "A hospitalized patient undergoing Therapeutic Drug Monitoring (TDM) for phenytoin has a measured total phenytoin trough concentration of $C_{\\mathrm{meas}} = 7.480$ $\\mu\\mathrm{g}/\\mathrm{mL}$ and a serum albumin concentration of $\\mathrm{Alb} = 2.30$ $\\mathrm{g}/\\mathrm{dL}$. Phenytoin is a highly albumin-bound drug, and within the therapeutic range it is reasonable to model binding to albumin using a single dominant class of reversible binding sites governed by mass action. The core definitions and facts used in TDM are that the free concentration $C_{\\mathrm{free}}$ is pharmacologically active, the total concentration satisfies $C_{\\mathrm{total}} = \\frac{C_{\\mathrm{free}}}{f_{u}}$ where $f_{u}$ is the free (unbound) fraction, and comparisons across patients should preserve the same $C_{\\mathrm{free}}$ to assess equivalence of pharmacologic effect.\n\nStarting from the mass-action binding equilibrium for a single-site reversible interaction between phenytoin and albumin, and using the above TDM relationship between $C_{\\mathrm{total}}$, $C_{\\mathrm{free}}$, and $f_{u}$, derive an expression that maps the patient’s measured total concentration $C_{\\mathrm{meas}}$ at albumin $\\mathrm{Alb}$ to the total concentration that would be observed in a reference state with normal binding (defined by a normal free fraction $f_{u,n} = 0.10$), assuming that over the clinically relevant phenytoin concentration range the free fraction is empirically well-approximated by an inverse-linear calibration of albumin as\n$$\nf_{u}(\\mathrm{Alb}) \\approx \\frac{f_{u,n}}{\\alpha \\,\\mathrm{Alb} + \\beta},\n$$\nwith calibration constants $\\alpha = 0.20$ and $\\beta = 0.10$ (albumin in $\\mathrm{g}/\\mathrm{dL}$). Use this derivation to obtain a closed-form expression for the adjusted total concentration at normal binding, $C_{\\mathrm{adj}}$, in terms of $C_{\\mathrm{meas}}$, $\\mathrm{Alb}$, $\\alpha$, and $\\beta$, and then compute the numerical value of $C_{\\mathrm{adj}}$ for the given patient data. Express your final answer in $\\mu\\mathrm{g}/\\mathrm{mL}$ and round to four significant figures.\n\nIn your reasoning, articulate the fundamental assumptions that justify using the above inverse-linear calibration for $f_{u}(\\mathrm{Alb})$ in clinical practice, and explain the scientific limitations of this correction under conditions such as end-stage renal disease, significant hyperbilirubinemia, coadministration of displacing drugs, or markedly altered albumin affinity. The final numeric answer must be a single real-valued number.", "solution": "The problem statement is evaluated to be scientifically sound, well-posed, and objective. All necessary data and definitions are provided, and the premises are consistent with established principles of clinical pharmacology and therapeutic drug monitoring (TDM). The problem is therefore deemed valid and a full solution will be provided.\n\nThe fundamental principle underlying the adjustment of a measured drug concentration in TDM is the preservation of the pharmacologically active free drug concentration, $C_{\\mathrm{free}}$. The objective is to calculate an adjusted total concentration, $C_{\\mathrm{adj}}$, that would produce the same free concentration in a patient with normal protein binding as the free concentration that exists in the actual patient with altered protein binding.\n\nLet the patient's measured state be defined by the measured total concentration, $C_{\\mathrm{meas}}$, and the patient's specific serum albumin concentration, $\\mathrm{Alb}$. The free fraction in the patient, $f_{u}(\\mathrm{Alb})$, is a function of their albumin level. The free drug concentration in the patient is given by the standard TDM relationship:\n$$C_{\\mathrm{free, patient}} = C_{\\mathrm{meas}} \\times f_{u}(\\mathrm{Alb})$$\n\nThe reference state is defined by a normal serum albumin level, which corresponds to a normal free fraction, $f_{u,n}$. The adjusted total concentration, $C_{\\mathrm{adj}}$, is the hypothetical total concentration in this reference state that yields the equivalent free concentration.\n$$C_{\\mathrm{free, reference}} = C_{\\mathrm{adj}} \\times f_{u,n}$$\n\nBy equating the free concentrations to ensure equivalent pharmacologic effect, we establish the core relationship for the adjustment:\n$$C_{\\mathrm{free, patient}} = C_{\\mathrm{free, reference}}$$\n$$C_{\\mathrm{meas}} \\times f_{u}(\\mathrm{Alb}) = C_{\\mathrm{adj}} \\times f_{u,n}$$\n\nSolving for the adjusted concentration, $C_{\\mathrm{adj}}$, we obtain:\n$$C_{\\mathrm{adj}} = C_{\\mathrm{meas}} \\frac{f_{u}(\\mathrm{Alb})}{f_{u,n}}$$\n\nThe problem provides an empirical model for the free fraction as a function of the albumin concentration, $\\mathrm{Alb}$ (in units of $\\mathrm{g}/\\mathrm{dL}$):\n$$f_{u}(\\mathrm{Alb}) = \\frac{f_{u,n}}{\\alpha \\,\\mathrm{Alb} + \\beta}$$\nwhere $\\alpha$ and $\\beta$ are dimensionless calibration constants derived from population data.\n\nSubstituting this empirical formula into the expression for $C_{\\mathrm{adj}}$ yields:\n$$C_{\\mathrm{adj}} = C_{\\mathrm{meas}} \\frac{\\left(\\frac{f_{u,n}}{\\alpha \\,\\mathrm{Alb} + \\beta}\\right)}{f_{u,n}}$$\n\nThe term $f_{u,n}$ cancels out, leading to a simplified, closed-form expression for the adjusted concentration:\n$$C_{\\mathrm{adj}} = \\frac{C_{\\mathrm{meas}}}{\\alpha \\,\\mathrm{Alb} + \\beta}$$\nThis equation, often known as the Sheiner-Tozer equation, allows for the direct calculation of an albumin-adjusted phenytoin concentration.\n\nThe problem asks for a discussion of the assumptions and limitations. The initial reference to \"mass-action binding equilibrium\" is critical context. For a single-site reversible interaction, Drug + Albumin $\\leftrightarrow$ Drug-Albumin, the law of mass action leads to the relationship $f_u = (1 + K_A [\\text{Albumin}])^{-1}$, where $K_A$ is the association constant. This can be rearranged to $f_u^{-1} = 1 + K_A [\\text{Albumin}]$, which shows that the inverse of the free fraction is linearly related to the albumin concentration, assuming the drug concentration is not high enough to cause saturation. The empirical formula provided, $f_{u}(\\mathrm{Alb})^{-1} = (\\alpha/f_{u,n})\\mathrm{Alb} + (\\beta/f_{u,n})$, is of the same linear form. This demonstrates that the empirical model is consistent with the underlying physical chemistry of binding, which justifies its use.\n\nHowever, this model rests on several critical assumptions:\n1.  The relationship between $f_u$ and $\\mathrm{Alb}$ is determined solely by the albumin concentration.\n2.  The binding affinity (association constant $K_A$) of phenytoin to albumin is unchanged in the patient compared to the reference population from which the formula was calibrated.\n3.  The concentration of phenytoin is not high enough to cause saturation of albumin binding sites, such that $f_u$ is independent of the total drug concentration.\n\nThe scientific limitations of this correction formula become apparent when these assumptions are violated:\n1.  **End-stage renal disease (uremia):** Uremic toxins accumulate in the blood and act as endogenous displacing agents, binding to albumin and reducing the number of sites available for phenytoin. This effectively lowers the binding affinity for phenytoin, increasing $f_u$ beyond what is predicted by the albumin concentration alone.\n2.  **Significant hyperbilirubinemia:** High concentrations of bilirubin, another substance that binds strongly to albumin, will competitively displace phenytoin, again invalidating the simple albumin-based correction.\n3.  **Coadministration of displacing drugs:** Concomitant therapy with other highly protein-bound drugs that share binding sites with phenytoin (e.g., valproic acid, salicylates) will lead to competitive displacement and an unpredictably higher free fraction.\n4.  **Markedly altered albumin affinity:** Genetic variants of albumin or post-translational modifications (e.g., glycosylation in diabetes) can alter the protein's three-dimensional structure and its affinity for drugs, rendering the standard correction formula inaccurate.\nIn such complex clinical scenarios, the correction formula may be unreliable, and direct measurement of the free phenytoin concentration is the preferred, more accurate approach.\n\nWe now proceed to the numerical calculation using the derived expression.\nThe given values are:\nMeasured total concentration, $C_{\\mathrm{meas}} = 7.480$ $\\mu\\mathrm{g}/\\mathrm{mL}$\nSerum albumin concentration, $\\mathrm{Alb} = 2.30$ $\\mathrm{g}/\\mathrm{dL}$\nCalibration constant, $\\alpha = 0.20$\nCalibration constant, $\\beta = 0.10$\n\nSubstituting these values into the derived formula for $C_{\\mathrm{adj}}$:\n$$C_{\\mathrm{adj}} = \\frac{7.480}{0.20 \\times 2.30 + 0.10}$$\nFirst, we calculate the value of the denominator:\n$$0.20 \\times 2.30 + 0.10 = 0.46 + 0.10 = 0.56$$\nNow, we compute the final value for $C_{\\mathrm{adj}}$:\n$$C_{\\mathrm{adj}} = \\frac{7.480}{0.56} = 13.357142... \\,\\, \\mu\\mathrm{g}/\\mathrm{mL}$$\n\nRounding the result to four significant figures as required by the problem statement, we get:\n$$C_{\\mathrm{adj}} = 13.36 \\,\\, \\mu\\mathrm{g}/\\mathrm{mL}$$\nThis adjusted concentration represents the total phenytoin level that would be expected in a patient with a normal albumin concentration ($4.5$ $\\mathrm{g}/\\mathrm{dL}$ in this model) to achieve the same free, pharmacologically active concentration as the current patient.", "answer": "$$\\boxed{13.36}$$", "id": "4584994"}, {"introduction": "We now advance to the forefront of TDM with model-informed precision dosing (MIPD), using a Bayesian framework to personalize therapy. This practice demonstrates how to formally combine prior knowledge about a drug's behavior in a population with new, patient-specific data to refine our estimate of an individual's pharmacokinetic parameters. By calculating a Bayesian dose recommendation and its associated uncertainty, you will engage with the quantitative methods that enable truly individualized drug therapy [@problem_id:4585032].", "problem": "A critically ill adult is receiving a constant intravenous infusion of a narrow-therapeutic-index antibiotic that requires Therapeutic Drug Monitoring (TDM). Under linear pharmacokinetics for a one-compartment model with time-invariant parameters, the steady-state concentration satisfies the mass-balance relation that for a constant infusion rate $R_{0}$ and clearance $CL$, the steady-state concentration is $C_{ss} = R_{0}/CL$. The clinical target is $C_{target} = 15$ mg/L, and the decision rule is to choose an infusion rate that would achieve $C_{target}$ if $CL$ equaled its posterior mean under a Bayesian update.\n\nPopulation information and covariates yield a prior for clearance modeled as a Normal distribution $CL \\sim \\mathcal{N}(\\mu_{0}, \\tau_{0}^{2})$ with $\\mu_{0} = 3.5$ L/h and $\\tau_{0} = 0.8$ L/h. A short rich-sampling TDM session provides a noncompartmental, asymptotically efficient estimate $\\hat{CL}$ that is approximately unbiased for $CL$ with sampling distribution $\\hat{CL} \\mid CL \\sim \\mathcal{N}(CL, \\sigma^{2})$, where the standard error is $\\sigma = 0.4$ L/h, and the observed value is $\\hat{CL} = 4.6$ L/h.\n\nStarting from Bayes’ theorem and these modeling assumptions, derive the posterior distribution for $CL$ and then define the Bayesian dose recommendation $R_{0}^{\\ast}$ by the rule $R_{0}^{\\ast} = C_{target} \\cdot \\mathbb{E}[CL \\mid \\text{data}]$. Quantify the uncertainty in this recommendation by the posterior variance $\\operatorname{Var}(R_{0} \\mid \\text{data})$, computed under the posterior for $CL$.\n\nCompute numerically the value of $R_{0}^{\\ast}$ in mg/h and the value of $\\operatorname{Var}(R_{0} \\mid \\text{data})$ in (mg/h)$^{2}$. Round each of the two numerical results to three significant figures. Provide both numbers as your final result.", "solution": "### Step 1: Extract Givens\n-   **Model:** Linear pharmacokinetics, one-compartment, time-invariant parameters.\n-   **Steady-state relation:** $C_{ss} = R_{0}/CL$, where $R_{0}$ is the constant infusion rate and $CL$ is the clearance.\n-   **Clinical Target:** $C_{target} = 15$ mg/L.\n-   **Prior Distribution for Clearance ($CL$):** $CL \\sim \\mathcal{N}(\\mu_{0}, \\tau_{0}^{2})$ with prior mean $\\mu_{0} = 3.5$ L/h and prior standard deviation $\\tau_{0} = 0.8$ L/h.\n-   **TDM Data Model (Likelihood):** The estimate $\\hat{CL}$ has a sampling distribution $\\hat{CL} \\mid CL \\sim \\mathcal{N}(CL, \\sigma^{2})$.\n-   **TDM Data Values:** The observed value is $\\hat{CL} = 4.6$ L/h, with a standard error of $\\sigma = 0.4$ L/h.\n-   **Decision Rule for Dose:** The recommended infusion rate $R_{0}^{\\ast}$ is defined by $R_{0}^{\\ast} = C_{target} \\cdot \\mathbb{E}[CL \\mid \\text{data}]$.\n-   **Definition of Uncertainty:** The uncertainty in the recommendation is quantified by the posterior variance $\\operatorname{Var}(R_{0} \\mid \\text{data})$, where $R_{0} = C_{target} \\cdot CL$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity.\n-   **Scientifically Grounded:** The problem is based on standard, well-established principles of clinical pharmacology and pharmacometrics, including one-compartment models, steady-state kinetics ($C_{ss} = R_{0}/CL$), and Bayesian inference. The use of a normal prior and a normal likelihood (a conjugate pair) is a standard technique in Bayesian statistics.\n-   **Well-Posed:** All necessary parameters and models are provided. The objectives are clearly stated: derive the posterior distribution, compute the recommended dose $R_{0}^{\\ast}$, and compute its posterior variance. A unique, stable solution is attainable from the given information.\n-   **Objective:** The problem is stated in precise, quantitative, and unbiased language.\n\nThe problem is self-contained, scientifically sound, and well-posed. No flaws are identified.\n\n### Step 3: Verdict and Action\nThe problem is valid. A full solution will be provided.\n\n### Derivation of the Posterior Distribution for Clearance ($CL$)\nThe posterior distribution of $CL$ given the observed data $\\hat{CL}$ is derived using Bayes' theorem. The posterior probability density function, $p(CL \\mid \\hat{CL})$, is proportional to the product of the likelihood function, $p(\\hat{CL} \\mid CL)$, and the prior distribution, $p(CL)$.\n\nThe prior distribution for $CL$ is Normal:\n$$p(CL) = \\frac{1}{\\sqrt{2\\pi\\tau_{0}^{2}}} \\exp\\left(-\\frac{(CL - \\mu_{0})^2}{2\\tau_{0}^{2}}\\right)$$\n\nThe likelihood function, based on the sampling distribution of $\\hat{CL}$, is also Normal:\n$$p(\\hat{CL} \\mid CL) = \\frac{1}{\\sqrt{2\\pi\\sigma^{2}}} \\exp\\left(-\\frac{(\\hat{CL} - CL)^2}{2\\sigma^{2}}\\right)$$\n\nThe posterior density is therefore:\n$$p(CL \\mid \\hat{CL}) \\propto p(\\hat{CL} \\mid CL) \\cdot p(CL)$$\n$$p(CL \\mid \\hat{CL}) \\propto \\exp\\left(-\\frac{(\\hat{CL} - CL)^2}{2\\sigma^{2}}\\right) \\cdot \\exp\\left(-\\frac{(CL - \\mu_{0})^2}{2\\tau_{0}^{2}}\\right)$$\n$$p(CL \\mid \\hat{CL}) \\propto \\exp\\left( -\\frac{1}{2} \\left[ \\frac{(\\hat{CL} - CL)^2}{\\sigma^{2}} + \\frac{(CL - \\mu_{0})^2}{\\tau_{0}^{2}} \\right] \\right)$$\n\nTo identify the parameters of the posterior distribution, we complete the square for $CL$ in the exponent. The term inside the square brackets is:\n$$\\frac{CL^2 - 2CL\\hat{CL} + \\hat{CL}^2}{\\sigma^2} + \\frac{CL^2 - 2CL\\mu_0 + \\mu_0^2}{\\tau_0^2}$$\n$$= CL^2 \\left(\\frac{1}{\\sigma^2} + \\frac{1}{\\tau_0^2}\\right) - 2CL \\left(\\frac{\\hat{CL}}{\\sigma^2} + \\frac{\\mu_0}{\\tau_0^2}\\right) + \\text{terms not involving } CL$$\n\nThis quadratic form in $CL$ indicates that the posterior distribution is also Normal, which we denote as $CL \\mid \\hat{CL} \\sim \\mathcal{N}(\\mu_{1}, \\tau_{1}^{2})$. The general form of the exponent for this posterior is $-\\frac{(CL-\\mu_1)^2}{2\\tau_1^2} = -\\frac{1}{2\\tau_1^2}(CL^2 - 2CL\\mu_1 + \\mu_1^2)$.\n\nBy comparing the coefficients of the $CL^2$ term, we find the posterior precision ($1/\\tau_1^2$):\n$$\\frac{1}{\\tau_1^2} = \\frac{1}{\\tau_0^2} + \\frac{1}{\\sigma^2}$$\nThe posterior variance, $\\tau_1^2$, is the reciprocal of the sum of the prior and data precisions.\n\nBy comparing the coefficients of the $CL$ term, we find the posterior mean, $\\mu_1$:\n$$\\frac{\\mu_1}{\\tau_1^2} = \\frac{\\mu_0}{\\tau_0^2} + \\frac{\\hat{CL}}{\\sigma^2}$$\n$$\\mu_1 = \\tau_1^2 \\left(\\frac{\\mu_0}{\\tau_0^2} + \\frac{\\hat{CL}}{\\sigma^2}\\right)$$\nThis shows the posterior mean is a precision-weighted average of the prior mean and the observed data.\n\n### Calculation of the Dose Recommendation ($R_{0}^{\\ast}$)\nThe recommended dose $R_{0}^{\\ast}$ is defined by the rule:\n$$R_{0}^{\\ast} = C_{target} \\cdot \\mathbb{E}[CL \\mid \\text{data}]$$\nThe expectation of $CL$ under the posterior distribution is the posterior mean, $\\mu_1$.\n$$R_{0}^{\\ast} = C_{target} \\cdot \\mu_1$$\n\n### Calculation of the Posterior Variance of the Infusion Rate\nThe uncertainty in the infusion rate is quantified by its posterior variance. The infusion rate $R_0$ is treated as a random variable functionally dependent on the random variable $CL$: $R_0 = C_{target} \\cdot CL$. The posterior variance is:\n$$\\operatorname{Var}(R_{0} \\mid \\text{data}) = \\operatorname{Var}(C_{target} \\cdot CL \\mid \\text{data})$$\nSince $C_{target}$ is a constant, we use the variance property $\\operatorname{Var}(aX) = a^2 \\operatorname{Var}(X)$:\n$$\\operatorname{Var}(R_{0} \\mid \\text{data}) = C_{target}^2 \\cdot \\operatorname{Var}(CL \\mid \\text{data})$$\nThe variance of $CL$ under the posterior distribution is $\\tau_1^2$.\n$$\\operatorname{Var}(R_{0} \\mid \\text{data}) = C_{target}^2 \\cdot \\tau_1^2$$\n\n### Numerical Computation\nWe are given:\n-   $C_{target} = 15$ mg/L\n-   $\\mu_{0} = 3.5$ L/h\n-   $\\tau_{0} = 0.8$ L/h $\\implies \\tau_{0}^2 = 0.64$ (L/h)$^2$\n-   $\\hat{CL} = 4.6$ L/h\n-   $\\sigma = 0.4$ L/h $\\implies \\sigma^2 = 0.16$ (L/h)$^2$\n\nFirst, calculate the posterior variance $\\tau_1^2$:\n$$\\frac{1}{\\tau_1^2} = \\frac{1}{\\tau_0^2} + \\frac{1}{\\sigma^2} = \\frac{1}{0.64} + \\frac{1}{0.16} = 1.5625 + 6.25 = 7.8125 \\text{ (L/h)}^{-2}$$\n$$\\tau_1^2 = \\frac{1}{7.8125} = 0.128 \\text{ (L/h)}^2$$\n\nNext, calculate the posterior mean $\\mu_1$:\n$$\\mu_1 = \\tau_1^2 \\left(\\frac{\\mu_0}{\\tau_0^2} + \\frac{\\hat{CL}}{\\sigma^2}\\right) = (0.128) \\left(\\frac{3.5}{0.64} + \\frac{4.6}{0.16}\\right)$$\n$$\\mu_1 = (0.128) (5.46875 + 28.75) = (0.128) (34.21875) = 4.38 \\text{ L/h}$$\n\nNow, compute the recommended dose $R_{0}^{\\ast}$:\n$$R_{0}^{\\ast} = C_{target} \\cdot \\mu_1 = 15 \\text{ mg/L} \\cdot 4.38 \\text{ L/h} = 65.7 \\text{ mg/h}$$\nRounding to three significant figures, $R_{0}^{\\ast} = 65.7$ mg/h.\n\nFinally, compute the posterior variance of the infusion rate, $\\operatorname{Var}(R_{0} \\mid \\text{data})$:\n$$\\operatorname{Var}(R_{0} \\mid \\text{data}) = C_{target}^2 \\cdot \\tau_1^2 = (15 \\text{ mg/L})^2 \\cdot 0.128 \\text{ (L/h)}^2$$\n$$\\operatorname{Var}(R_{0} \\mid \\text{data}) = 225 \\text{ (mg/L)}^2 \\cdot 0.128 \\text{ (L/h)}^2 = 28.8 \\text{ (mg/h)}^2$$\nRounding to three significant figures, $\\operatorname{Var}(R_{0} \\mid \\text{data}) = 28.8$ (mg/h)$^{2}$.\n\nThe two requested numerical results are the recommended infusion rate $R_{0}^{\\ast}$ and the posterior variance $\\operatorname{Var}(R_{0} \\mid \\text{data})$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 65.7 & 28.8 \\end{pmatrix}}\n$$", "id": "4585032"}]}